Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0684249 (lung carcinoma)
 23,830 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The antitumor activity of ASTA Z 7557, a stabilized primary metabolite of cyclophosphamide, was evaluated in comparison with cyclophosphamide (CP) against different rodent tumor systems. At equimolar doses, which corresponded in mg/kg to the optimal doses of each compound, Z 7557 showed a higher therapeutic activity than CP when both drugs were administered intraperitoneally (ip) during 5 consecutive days. The drug remained active against a P388 subline totally resistant to CP, but to a much lesser extent. The ip-implanted B16 melanoma was highly sensitive to 100 and 50 mg/kg administered during 9 consecutive days: an increase in lifespan (ILS) of 244% was produced and 5 mice out of 10 were cured. This treatment administered against Lewis lung carcinoma (LL) transplanted intravenously (iv) induced an ILS of 179% and 3 mice out of 10 survived on day 60. This effect was slightly inferior to that produced by 50 mg/kg of CP, but is balanced by the number of long-term survivors recorded after administration of low doses of Z 7557. When mice bearing the subcutaneously (sc) implanted colon 38 (C38) tumor were treated with 200 mg/kg on days 2 and 9, the tumor growth was inhibited by 83% in comparison to the control mice. The wide range of activity of Z 7557, its stability and its different chemical reactivity as compared to CP appear to justify interest in this activated oxazaphosphorine.
 ...
PMID:Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumors. 646 11

Changes of biological properties, DNA-distribution patterns and drug sensitivity testing in vivo and in vitro after different culture and transplantation conditions in case of a human lung carcinoma are described. While DNA-distribution patterns of cells before any culture (OSC, TC 0) showing two clearly different aneuploid cell populations (DNA-index DI: 3.9 and 4.9), cells after 8 passages (TC 8) in vitro demonstrate only one cell population. These cells do not differ from double value (4C) of diploid cells (2C). DNA-distribution patterns of cells of solid tumors grown in nude mice (nu/nu 2089-1) show a cell population with DI 6.3. In line with these results, cells and tissues after different culture and transplantation conditions exhibit variable drug sensitivities. The lung carcinoma (OSC) shows clear reactions measured either by 3H-thymidine or 3H-deoxyuridine in the presence of Cyclophosphamide and Methotrexate. Adriblastin and 5-Fluorouracil did not show any effects after 48 hours treatment. Cultivated cells (TC 8) were sensitive against all antineoplastic drugs tested. Tumor tissue grown in nude mice (nu/nu 2089-1) shows the strongest effect after 5-Fluorouracil treatment both in vitro and in vivo. Selection of different cell population were discussed with regard to these findings.
 ...
PMID:Investigations on the instability of drug sensitivity in dependence on culture and transplantation conditions in case of a human lung carcinoma. 652 19

A metastasizing tumour model in which a non-immunogenic tumor (Lewis lung carcinoma) is implanted in the caecum of syngeneic mice, is described. The most interesting property of this model is the formation of spontaneous hepatic and transperitoneal metastases. Resection of the caecum tumor 14 days after implantation leaves micrometastases in liver, peritoneum and lungs. This gives the opportunity for the study of adjuvant therapy. Adjuvant chemotherapy with cyclophosphamide cured a significant percentage of animals with micrometastases in liver and peritoneum. Cyclophosphamide therapy had no effect on micrometastases in liver and peritoneum when the primary tumor was left in place. This finding underlines the importance of aggressive treatment of the primary tumor before adjuvant chemotherapy can be effective in colorectal cancer.
 ...
PMID:Adjuvant chemotherapy in a new metastasizing caecum tumor model. 654 8

A series of acridine monosubstituted derivatives of the antitumour agent amsacrine [4'-(9-acridinylamino)methanesulphon-m-anisidide] has been tested for activity against intraperitoneally inoculated P388 leukaemia and intravenously inoculated Lewis lung carcinoma growing in DBA/2J X C57BL/6J mice, and treated using a q4d X 3 intraperitoneal injection schedule. Whereas all derivatives tested exhibited moderate to high activity towards the leukaemia, activity against the lung tumour varied from inactive to curative. Amsacrine itself displayed low but statistically significant activity. Cyclophosphamide and 2-beta-D-ribofuranosylthiazole-4-carboxamide (tiazofurin) were highly active. 5-Fluorouracil was active but doxorubicin, daunorubicin, ametantrone and mitoxantrone showed no significant activity. Since the Lewis lung carcinoma is responsive to a high proportion of agents active against solid tumours in the clinic, it is concluded that some derivatives of amsacrine could be considerably more active than amsacrine itself against human solid tumours.
 ...
PMID:Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in mice. 668 94

A synchronised programme consisting of VCR, CTX and MTX has been employed in 57 patients suffering fom lung carcinoma. Average survival was 10.6 months and overall tolerance was good. The best indications are intermittent long-term treatment and retreatment of patients with cancer recalcitrant to the same drugs. With the simplification of cell kinetics study techniques, more meaningful results can be expected in the application of this treatment programme.
 ...
PMID:[Use of a synchronized protocol of cytostatic drugs in the treatment of advanced lung cancer]. 725 20

Fifty-eight patients with non-small cell carcinoma of the lung (33 with epidermoid carcinoma, 22 with adenocarcinoma, and three with large cell anaplastic carcinoma) were treated with high-dose cyclophosphamide (CTX) or, alternatively, with CTX, methotrexate, 5-FU, and hydroxyurea (CMFH) in a controlled study. Two partial remissions were achieved (one in each regimen [13%]. Seventeen of 29 patients treated with CTX and 14 of 29 patients treated with CMFH showed no change (differences were not statistically significant). Toxicity was moderate in both regimens. Median survival was 24 weeks for patients treated with CTX and 26 weeks for patients treated with CMFH (differences were not significant). The results show that the therapeutic activity of CMFH is not higher than that of CTX alone.
 ...
PMID:High-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trial. 745 99

The effect of combined surgical and chemotherapeutic treatment on Lewis lung carcinoma was studied. The i.m. implanted primary tumor was removed on the 10th day after transplantation, and the survival of mice was registered. Cyclophosphamide proved to be the most effective among the drugs studied (Cyclophosphamide, 5-FU, DBD, CCNU, Adriamycin, Vincristin, Hexyldeoxyuridine). Using different schedules (pre- and/or post-operative treatment) the pre- and post-operative drug administration was the most advantageous. Combined therapy showed always better effect than monotherapy.
 ...
PMID:Effect of combined surgical and chemotherapeutic treatment of Lewis lung carcinoma. 746 95

Sixteen patients with extensive non-small carcinoma of the lung were treated with methotrexate, vincristine, cyclophosphamide, and adriamycin. Cyclophosphamide and adriamycin were administered after pretreatment with amphotericin B. Amphotericin B-related toxicity was mild; cytotoxic chemotherapy-related toxicity was tolerable. The partial response rate was 12.5% and median survival was between 19 and 20 weeks. Response rate and survival were not superior to those of a similar drug combination lacking amphotericin B.
 ...
PMID:Amphotericin B plus combination chemotherapy for extensive non-small cell bronchogenic carcinoma. 747 19

Presentation of the "de novo" tumours developed in two series of renal transplant receptors over the last 16 years. The first series, Historic, comprises the group of 178 patients who were given Azathioprin or Cyclophosphamide plus Prednisone for immunosuppression. The second series, Current, includes 129 patients who received immunosuppressive therapy with Cyclosporin A. Overall incidence of these "de novo" malignant tumours was 4% (13/307), 9 of which corresponded to the Historic Series (incidence, 5%) and 4 to the Current Series (incidence, 3%). Mean time interval from transplantation to diagnosis was 87.3 months (range, 9-177) in the Historic Series and 34.5 (range, 8-67) in the Current Series, the difference being statistically significant (p = 0.02). By locations, skin and lip tumours represent 38.5%, followed in frequency by lymphoma (23%) and lung carcinoma (15%). No urological tumours were recorded.
 ...
PMID:["De novo" malignant tumors in kidney transplant receptors]. 797 11

This trial was carried out to assess the response rate and survival benefit achieved, if any, by substitution of etoposide for doxorubicin and addition of methotrexate in combination with cyclophosphamide and vincristine in the treatment of 113 patients with small cell lung carcinoma (SCLC). Cyclophosphamide, etoposide, vincristine, methotrexate (CEV-M) yielded a response rate of 75% in localized disease (LD) and 63% in extensive disease (ED), versus 61% in LD and 52% in ED in the cyclophosphamide, doxorubicin, vincristine (CAV) arm. There was also a significant survival benefit for the responders in favor of CEV-M (21.7 +/- 3.8 months of median survival compared to 13.6 +/- 2.8 months in CAV arm) in patients with LD.
 ...
PMID:A randomized study comparing cyclophosphamide, doxorubicin, vincristine (CAV) with cyclophosphamide, etoposide, vincristine, methotrexate (CEVM) in patients with small cell lung cancer. 838 59


<< Previous 1 2 3 4 5 6 Next >>